PTH and carcinoma: MEK/ERK has been proposed as a crucial regulator of cell fate choices based on its differential activation kinetics to transient vs. sustained stimuli in fibroblasts, neural and carcinoma cells [51–53] and to intermittent vs. continuous PTH in PTH-responsive kidney cells [33, 54].